FPI-2053 / AstraZeneca - LARVOL DELTA

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: AstraZeneca | N=169 ➔ 70 | Trial completion date: Dec 2027 ➔ May 2028 | Trial primary completion date: Dec 2026 ➔ May 2028

Enrollment change • First-in-human • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastric Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=169 | Recruiting | Sponsor: Fusion Pharmaceuticals Inc. | N=110 ➔ 169

Enrollment change • Colorectal Cancer • Gastric Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A First-in-Human Study of the Radiopharmaceutical [225Ac]-FPI-2068 in Patients (pts) with Advanced Solid Tumors (ASTRO 2024) - P1 | "[225Ac]-FPI-2068 (FPI-2068) is an EGFR/c-MET targeting bispecific antibody (FPI-2053) linked to the alpha emitting radioisotope actinium-225 which has shown to have promising efficacy in preclinical tumor models. TBD"

Clinical • Metastases • P1 data • Cardiovascular • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • MET

A Phase 1, First-in-human, Multicentre, Open-label, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumors (SNMMI 2024) - P1 | "[225Ac]-FPI-2068 is an EGFR/c-MET targeting bispecific antibody (FPI-2053) linked to the alpha emitting radioisotope actinium-225 which has been shown to have promising efficacy in a range of preclinical tumor models. This is a Trial in Progress."

Clinical • Metastases • P1 data • Cardiovascular • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • MET

A Phase 1, First-in-human, Multicentre, Open-label, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumors (SNMMI 2024) - P1 | "[225Ac]-FPI-2068 is an EGFR/c-MET targeting bispecific antibody (FPI-2053) linked to the alpha emitting radioisotope actinium-225 which has been shown to have promising efficacy in a range of preclinical tumor models. This is a Trial in Progress."

Clinical • Metastases • P1 data • Cardiovascular • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • MET

A Phase 1, First-in-human, Multicentre, Open-label, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumors (SNMMI 2024) - P1 | "[225Ac]-FPI-2068 is an EGFR/c-MET targeting bispecific antibody (FPI-2053) linked to the alpha emitting radioisotope actinium-225 which has been shown to have promising efficacy in a range of preclinical tumor models. This is a Trial in Progress."

Clinical • Metastases • P1 data • Cardiovascular • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • MET

A Phase 1, First-in-human, Multicentre, Open-label, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumors (SNMMI 2024) - P1 | "[225Ac]-FPI-2068 is an EGFR/c-MET targeting bispecific antibody (FPI-2053) linked to the alpha emitting radioisotope actinium-225 which has been shown to have promising efficacy in a range of preclinical tumor models. This is a Trial in Progress."

Clinical • Metastases • P1 data • Cardiovascular • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • MET

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Fusion Pharmaceuticals Inc. | Initiation date: Feb 2024 ➔ Jun 2024

Metastases • Trial initiation date • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Fusion Pharmaceuticals Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck